Last reviewed · How we verify
NCT06087120: BRAVA
Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
trial in Breast Cancer Female in 125 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | Gene Solutions |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 125 |
| Start date | 16 September 2023 |
| Primary completion | 1 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 3 locations across Indonesia, Vietnam |
Conditions studied
- Breast Cancer Female — all drugs for Breast Cancer Female →
- Stage II Breast Cancer — all drugs for Stage II Breast Cancer →
- Stage III Breast Cancer — all drugs for Stage III Breast Cancer →
- HER2-positive Breast Cancer — all drugs for HER2-positive Breast Cancer →
Sponsor
Gene Solutions
Who can join
18 and older, female only, with Breast Cancer Female or Stage II Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment. * Determine the rate of ctDNA positivity at the time before treatment, * Determine the rate of ctDNA positivity at the time during treatment, * Determine the rate of ctDNA positivity at the time after neoadjuvant therapy, whether there is a change in ctDNA expression of the study population during treatment. And aiming to investigate the relationship between ctDNA expression and MRI imaging with pCR response in neo-adjuvant therapy: * Correlation between ctDNA detection and pCR response. Determine the percentage of Positive Prediction Value - PPV, Negative Prediction Value - NPV of ctDNA, * Correlation between MRI imaging and pCR response. Determination of PPV, NPV of MRI * Combination of ctDNA detection and MRI imaging in the prognosis of pCR. Determination of PPV, NPV ratio of ctDNA combined with MRI.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment.
Sabit H, Attia MG, Mohamed N, Taha PS, et al · · 2025 · cited 4× · PMID 40050490 · DOI 10.1007/s12672-025-01940-6 -
Liquid biopsy in breast cancer: Redefining precision medicine.
Schiavone ML, Scarpitta R, Ravera F, Bleve S, et al · · 2025 · cited 3× · PMID 40740670 · DOI 10.1016/j.jlb.2025.100312
Verify or expand the search:
- PubMed search for NCT06087120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Female
Currently open trials in the same condition.
- NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
- NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting
Other Gene Solutions trials
Trials by the same sponsor.
- NCT07126626 — Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer · not yet recruiting
- NCT06929910 — Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing. · recruiting
- NCT06385366 — Developing & Evaluating Models for Early Predicting Obstetrical Diseases in Pregnant Women by Non-invasive Prenatal Test · enrolling by invitation
- NCT06227728 — Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer. · recruiting
- NCT06167460 — Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06087120 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gene Solutions
- Last refreshed: 23 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06087120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing